Treatment of hemodialyzed patients with sunitinib in renal cell carcinoma

Chemotherapy

Volumn 56, Issue 6, 2010, Pages 485-491

  Park, Silvia ^a   Lee, Jeeyun ^a   Park, Se Hoon ^a   Park, Joon Oh ^a   Kang, Won Ki ^a   Park, Young Suk ^a   Cho, Jin Hyun ^a   Lim, Ho Yeong ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Hemodialysis; Renal cell carcinoma; Sunitinib, dose, toxicity, response

Indexed keywords

GAMMA INTERFERON; SORAFENIB; SUNITINIB;

ABDOMINAL PAIN; ADULT; AGED; AMYLASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTICLE; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RECURRENCE; CLINICAL ARTICLE; CLINICAL PRACTICE; DIARRHEA; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG RESPONSE; DRUG WITHDRAWAL; DYSPEPSIA; EPISTAXIS; FATIGUE; FEMALE; GAMMA KNIFE RADIOSURGERY; HAND FOOT SYNDROME; HEMATURIA; HEMODIALYSIS PATIENT; HEMOPTYSIS; HUMAN; KIDNEY CARCINOMA; LUNG METASTASIS; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHRECTOMY; NEUTROPENIA; PETECHIA; PIGMENT DISORDER; PRIORITY JOURNAL; PRURITUS; RETROSPECTIVE STUDY; SENSORY NEUROPATHY; SIDE EFFECT; STOMATITIS; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; DISEASE PROGRESSION; FEMALE; HUMANS; INDOLES; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PYRROLES; RENAL DIALYSIS; RETROSPECTIVE STUDIES;

EID: 78449250326     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000321033     Document Type: Article

References (26)

1. Chow WH, Devesa SS, Warren JL, Fraumeni JF Jr: Rising incidence of renal cell cancer in the United States. JAMA 1999; 281: 1628-1631.
2. Lam JS, Leppert JT, Belldegrun AS, Figlin RA: Novel approaches in the therapy of metastatic renal cell carcinoma. World J Urol 2005; 23: 202-212.
3. Motzer RJ, Bander NH, Nanus DM: Renalcell carcinoma. N Engl J Med 1996; 335: 865-875.
4. Janzen NK, Kim HL, Figlin RA, Belldegrun AS: Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am 2003; 30: 843-852.
5. Linehan WM, Walther MM, Zbar B: The genetic basis of cancer of the kidney. J Urol 2003; 170: 2163-2172.
6. Karumanchi SA, Merchan J, Sukhatme VP: Renal cancer: molecular mechanisms and newer therapeutic options. Curr Opin Nephrol Hypertens 2002; 11: 37-42.
7. Xiong X, Liu H, Fu L, Li L, Li J, Luo X, Mei C: Antitumor activity of a new N-substituted thiourea derivative, an EGFR signaling-targeted inhibitor against a panel of human lung cancer cell lines. Chemotherapy 2008; 54: 463-474.
8. Sevinc A, Camci C: 'Time is a GIFT in GIST' - the medical and paramedical perspective of a case with metastatic gastrointestinal stromal tumor. Chemotherapy 2009; 55: 11-14.
9. Chow LQ, Eckhardt SG: Sunitinib: from rational design to clinical efficacy. J Clin Oncol 2007; 25: 884-896.
10. Faivre S, Delbaldo C, Vera K, Robert C, Lozahic S, Lassau N, Bello C, Deprimo S, Brega N, Massimini G, Armand JP, Scigalla P, Raymond E: Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006; 24: 25-35.
11. Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, Ginsberg MS, Kim ST, Baum CM, DePrimo SE, Li JZ, Bello CL, Theuer CP, George DJ, Rini BI: Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24: 16-24.
12. Motzer RJ, Rini BI, Bukowski RM, Curti BD, George DJ, Hudes GR, Redman BG, Margolin KA, Merchan JR, Wilding G, Ginsberg MS, Bacik J, Kim ST, Baum CM, Michaelson MD: Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006; 295: 2516-2524. (Pubitemid 43854967)
13. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115-124.
14. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, Negrier S, Szczylik C, Pili R, Bjarnason GA, Garciadel- Muro X, Sosman JA, Solska E, Wilding G, Thompson JA, Kim ST, Chen I, Huang X, Figlin RA: Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009; 27: 3584-3590.
15. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L, Motzer RJ: Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356: 2271-2281. (Pubitemid 46849157)
16. Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, Chevreau C, Filipek M, Melichar B, Bajetta E, Gorbunova V, Bay JO, Bodrogi I, Jagiello-Gruszfeld A, Moore N: Bevacizumab plus interferon alfa- 2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007; 370: 2103-2111.
17. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM: Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356: 125-134.
18. Gore ME, Szczylik C, Porta C, Bracarda S, Bjarnason GA, Oudard S, Hariharan S, Lee SH, Haanen J, Castellano D, Vrdoljak E, Schoffski P, Mainwaring P, Nieto A, Yuan J, Bukowski R: Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded- access trial. Lancet Oncol 2009; 10: 757-763.
19. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors - European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
20. Peces R, Martinez-Ara J, Miguel JL, Arrieta J, Costero O, Gorriz JL, Picazo ML, Fresno M: Renal cell carcinoma co-existent with other renal disease: clinico-pathological features in pre-dialysis patients and those receiving dialysis or renal transplantation. Nephrol Dial Transplant 2004; 19: 2789-2796.
21. Ishikawa I: Present status of renal cell carcinoma in dialysis patients in Japan: questionnaire study in 2002. Nephron Clin Pract 2004; 97:c11-c16.
22. Miller DC, Schonlau M, Litwin MS, Lai J, Saigal CS: Renal and cardiovascular morbidity after partial or radical nephrectomy. Cancer 2008; 112: 511-520.
23. Shirasaki Y, Tsushima T, Nasu Y, Kumon H: Long-term consequence of renal function following nephrectomy for renal cell cancer. Int J Urol 2004; 11: 704-708. (Pubitemid 39387515)
24. Izzedine H, Etienne-Grimaldi MC, Renee N, Vignot S, Milano G: Pharmacokinetics of sunitinib in hemodialysis. Ann Oncol 2009; 20: 190-192.
25. Zastrow S, Froehner M, Platzek I, Novotny V, Wirth MP: Treatment of metastatic renal cell cancer with sunitinib during chronic hemodialysis. Urology 2009; 73: 868-870.
26. Reckova M, Kakalejcik M, Beniak J: Treatment of hemodialyzed patient with sunitinib. Ann Oncol 2009; 20: 392-393.